

(51) International Patent Classification:
C07D 487/04 (2006.01)(21) International Application Number:
PCT/IB2013/060631(22) International Filing Date:
4 December 2013 (04.12.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/737,157 14 December 2012 (14.12.2012) US(71) Applicant: **PFIZER LIMITED** [GB/GB]; Ramsgate Road, Sandwich Kent CT13 9NJ (GB).(72) Inventors: **OMOTO, Kiyoyuki**; c/o Pfizer Limited, Portway Building, Granta Park, Great Abington Cambridge, England CB21 6GP (GB). **OWEN, Robert McKenzie**; c/o Pfizer Limited, Portway Building, Granta Park, Great Abington Cambridge, England CB21 6GP (GB). **PRYDE, David Cameron**; c/o Pfizer Limited, Portway Building, Granta Park, Great Abington Cambridge, England CB21 6GP (GB). **WATSON, Christine Anne Louise**; c/o Pfizer Limited, Ramsgate Road, Sandwich Kent, England CT13 9NJ (GB). **TAKEUCHI, Mifune**; c/o Pfizer Limited, Ramsgate Road, Sandwich Kent, England CT13 9NJ (GB).(74) Agent: **LANE, Graham M.**; Pfizer Limited, Ramsgate Road, Sandwich Kent, England CT13 9NJ (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: IMIDAZOPYRIDAZINE DERIVATIVES AS GABAA RECEPTOR MODULATORS



(57) **Abstract:** Chemical Compounds The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5- c]pyridazine derivatives of formula (I) and pharmaceutically acceptable salts thereof, wherein R¹, R², R³, R⁴ and R⁵ are as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the GABA_A receptor. They are useful in the treatment of a number of conditions, including pain.